Odanacatib is the first of a new class of drugs for Osteoporosis

Following on from news about the emerging competitive landscape in osteoporosis, Pieter Droppert on the Biotech Strategy Blog considers in more detail Merck’s odanacatib, currently in phase III clinical trials.

Odanacatib is first of a new class of drugs for the treatment of osteoporosis known as cathepsin K inhibitors (CAT-K).  You can read more on Biotech Strategy Blog about this new product, its mechanism of action and the marketing strategy associated with its development.

, , , , , , , , , , , ,

error: Content is protected !!